Cargando…
FRI538 Discovery And Characterization Of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists For The Treatment Of Graves’ Disease
Disclosure: M.A. Fowler: Employee; Self; Crinetics Pharmaceuticals. Stock Owner; Self; Crinetics Pharmaceuticals. C. Regan: Employee; Self; Crinetics Pharmaceuticals. Stock Owner; Self; Crinetics Pharmaceuticals. J. Zhao: Employee; Self; Crinetics Pharmaceuticals. Stock Owner; Self; Crinetics Pharma...
Autores principales: | Fowler, Melissa A, Regan, Collin, Zhao, Jian, Coutinho, Eulalia, Fleck, Beth, Castellanos, Anel A, Muller, Eric, Johns, Michael, Tang, Yang, Sturchler, Emmanuel, Chen, Mi, Retting, Kelsey, Dalvie, Deepak, Betz, Stephen F, Markison, Stacy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555201/ http://dx.doi.org/10.1210/jendso/bvad114.1883 |
Ejemplares similares
-
SAT182 Effects Of An Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist In Rodent Models Of Primary Hyperparathyroidism (PHPT)
por: Antwan, Agnes S, et al.
Publicado: (2023) -
FRI567 Insulin Autoimmune Syndrome And Grave’s Disease
por: Skariah, Annie M, et al.
Publicado: (2023) -
FRI571 Maternal Graves’ Disease With Foetal Thyrotoxicosis And Goitre
por: Fennell, David, et al.
Publicado: (2023) -
FRI473 Central Hypothyroidism Following Neonatal Graves Presentation
por: Metzinger, Emily, et al.
Publicado: (2023) -
FRI513 Pathological Bone Fracture In An Adolescent With Graves’ Disease
por: Hayes Dorado, Juan Pablo, et al.
Publicado: (2023)